Board Stats

Navidea Biopharmaceuticals, Inc.

Y! IH NAVB EXPRESS NAVB Advanced Due Diligence NAVB Oldtimers Lounge TME Macrophage Therapeutics Tx Potential-McGrath Basic Immune Cell Functions Immune Cells M1 and M2 Basics 2022- Magical Mystery Tour of Macrophges

NAVB / Message Board

BOARD

GROUPS

Written By On Topic Only -- All Messages

Hide Replies

Keyword
Subject

Between			and
Rec'd By

Authored By
Minimum Recs

MSG #	SUBJECT	TYPE	AUTHOR	SENTIMENT	RECS	DATE POSTED
39063	CC:therapeutic constructs significantly reduce the rate of tumor growth by an ave 76%	GN	moneyonomics		0	3/23/2023 7:54:36 PM

39062	CC indications for NYSE-A compliance	GN	FIRAC		8	3/23/2023 3:11:04 PM

39061	CC:Manocept is very flexible, adaptable with great advantages over most other groups	GN	moneyonomics		3	3/22/2023 11:36:27 PM

39060	CC:UAB-Navidea study on 68GA Manocept Constructs more effective Tumor Binding	GN	moneyonomics		3	3/22/2023 8:27:30 PM

39059	CC question:Is filling Thx IND in 2024,that opens Manocept to the world,still target?	GN	moneyonomics		4	3/22/2023 4:24:06 PM

39058	CC long term view:there will be patent apps for M1/M2 reprogramming in other disease	GN	moneyonomics		2	3/22/2023 4:12:44 PM

39057	CC long term view:M1/M2 reprogramming opportunity to be able to shake up the world...	GN	moneyonomics		2	3/22/2023 4:08:34 PM

39056	Re: Is "shortly" the new "imminent"? Inquiring minds ...	GN	alf33		0	3/22/2023 2:52:52 PM

39055	Is "shortly" the new "imminent"? Inquiring minds ...	GN	Fall1980		3	3/22/2023 2:29:59 PM

39054	Re: Erika	GN	alf33		1	3/22/2023 12:38:39 PM

Go to Msg #

BOARDS Sign In for Filters